IWC
VTGN icon

Integrated Wealth Concepts’s VistaGen Therapeutics VTGN Stock Holding History

Integrated Wealth Concepts’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$126 Buy
+556
New +$335 ﹤0.01% 5788

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Integrated Wealth Concepts's VTGN Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in VistaGen Therapeutics (VTGN) in Q2 2026: 556 shares worth $126. The stake represents ﹤0.01% of the portfolio and ranks #5788 among its holdings.

49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Integrated Wealth Concepts held 556 shares of VistaGen Therapeutics worth $126 as of Q2 2026.
  • VistaGen Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #5788 holding.
  • 49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.